Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 1/20 | 0.30 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.30 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.30 |
| ▸ | ACR | P10323 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3039796 | 0.93 | LPAR1 (0.32) | LPAR1LPAR2LPAR3ACRKDM4E | |
| SCHEMBL3044308 | 0.85 | LPAR1 (0.35) | LPAR1LPAR2LPAR3ACRKDM4E | |
| SCHEMBL3049045 | 0.84 | TRPM8 (0.35) | LPAR1LPAR2LPAR3ACRKDM4E | |
| SCHEMBL3051292 | 0.83 | HDAC3 (0.36) | LPAR1LPAR2LPAR3ALDH1A1 | |
| SCHEMBL2339955 | 0.83 | CNR2 (0.34) | LPAR1LPAR2LPAR3ACRKDM4E | |
| SCHEMBL2338001 | 0.79 | NR1H4 (0.39) | LPAR1LPAR2LPAR3ACRKDM4E | |
| SCHEMBL2335317 | 0.79 | LPAR1 (0.38) | LPAR1LPAR2LPAR3KDM4EALDH1A1 | |
| SCHEMBL2332523 | 0.79 | MAPT (0.40) | LPAR1LPAR2LPAR3ACRKDM4E | |
| SCHEMBL2338262 | 0.77 | LPAR1 (0.50) | LPAR1LPAR2LPAR3 | |
| SCHEMBL2339543 | 0.77 | LPAR1 (0.42) | LPAR1LPAR2LPAR3ACRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010068775-A2 | ALKYNE ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | WO | disclosed |